Little data is available on the bleeding risk and outcomes of cancer patients with chronic
thrombocytopenia who underwent cardiac catheterization. We sought to assess the safety of …

BACKGROUND. Patients with cancer who have thrombocytopenia may experience acute
coronary syndromes (ACS), and the use of aspirin (ASA) poses an increased risk of …

Objective To assess early and late outcomes, including bleeding, in patients with
thrombocytopenia undergoing percutaneous coronary intervention (PCI). Patients and …

It is still controversial whether baseline thrombocytopenia is independently associated with
adverse events after percutaneous coronary intervention. We evaluated the influence of …

Background. Thrombocytopenia was intuitively considered to be associated with higher risk
of bleeding and multiple comorbidities after percutaneous coronary intervention (PCI) …

Platelets are crucial in the pathogenesis of acute coronary syndrome. Treatment for acute
coronary syndrome usually involves antiplatelet, anticoagulant, and antithrombotic therapy …

Background. In acute coronary syndromes (ACS), treated by combined antithrombotic
therapy and percutaneous coronary interventions (PCI), thrombocytopenia may occur. Our …

Objectives. This study sought to determine the frequency of thrombocytopenia and its
relation with clinical outcomes in high risk patients undergoing percutaneous coronary …

Background Acquired thrombocytopenia (TP) has been associated with short-and long-term
adverse outcomes after percutaneous coronary intervention (PCI), but the role of baseline …

The early and late ischemic and bleeding clinical outcomes according to baseline platelet
count after percutaneous coronary intervention (PCI) in patients with acute myocardial …